Octapharma USA, Inc.
Adam G. is a highly experienced medical professional currently serving as the Scientific and Medical Director for Critical Care at Octapharma USA, Inc. since July 2022. Adam evaluates emerging scientific advancements, supports pivotal clinical trials, and cultivates relationships with key opinion leaders in the coagulation and bleeding domains. Prior to Octapharma, Adam held the role of Medical Director for Early Development and Translational Medicine at Angion BioMedica, where contributions included leading the development of clinical trials and preclinical research programs. Adam's career also includes significant academic experience at Columbia University Irving Medical Center as an Assistant Professor of Anesthesiology, where multifaceted patient care and protocol development were key responsibilities. Adam holds an MD/PhD from Upstate Medical University and a Bachelor's degree in Molecular Biology from Binghamton University.
This person is not in any teams
Octapharma USA, Inc.
1 followers
Octapharma USA, headquartered in Paramus, N.J., is a subsidiary of Octapharma AG, a global human protein products powerhouse, dedicated to the research and manufacture of human proteins. We have been committed to patient care and medical innovation for 40 years. Octapharma is one of the largest human protein manufacturers in the world, developing and producing human proteins from human plasma and human cell lines. Since being established in 1983, Octapharma is a global healthcare company headquartered in Lachen, Switzerland. Our products are available in 118 countries and reach hundreds of thousands of patients every year.